BioRelianc?e Expands Commercial Capabiliti?es of Big Blue Assay
![](/46/pdcnewsitem/03/31/96/mPPdWM6hfYqA8uF.png)
BioReliance, Sigma-Aldrich Corporation’s biologics and early-development services business under SAFC Commercial (www.sigmaaldrich.com/safc), has expanded commercial availability of its exclusive Big Blue Transgenic Rodent Mutation (TRM) assay to identify and measure mutations in somatic tissue and germ cells. The assay enables follow-up testing of pharmaceutical and chemical products that have shown positive results in genotoxicity or carcinogenicity assays and can be used to investigate possible mutagenic modes of action. This test is now available for use with either mouse or rat subjects.
Big Blue TRM is the only assay of its kind on the market that
• Has been validated for application to measure mutations in both mice and rats, allowing the investigation of earlier results in both species
• Was developed through support from the National Institute of Environmental Health Sciences’ National Toxicology Program (NTP)
• Features mouse and rat strains designed to be identical to mouse and rat strains used in NTP carcinogenicity studies
• Is under the ownership and guidance of an original developer of the assay
• Features complete control of animal colonies to ensure animal availability
• Works with inbred homozygous mouse and rat lines to permit cross-breeding with other transgenic lines to investigate mutagenicity associated with disease conditions
• Offers comprehensive assay support and access to the expertise of BioReliance scientists.
Other differentiating factors of the Big Blue assay include
• Qualification to meet Organisation for Economic Co-operation and Development Test Guideline 488 requirements for evaluation of in vivo somatic cell and germ cell mutagenicity
• Endorsement by the International Working Group for Genetic Toxicology (IWGT)
• Recommendation by the European Chemicals Agency and referenced in ICH, FDA, EMEA, and EFSA Guidelines
• Robust mutant frequency detection (p<.00001)
• 3R alignment – previous in vivo mutation options used hundreds of animals compared to study sizes of 25
• The ability to investigate mutagenic mode of action after genotoxic positives in almost any tissue of the body.
BioReliance is making multiple presentations on the assay at this week’s Society of Toxicology’s 53rd Annual Meeting and Tox Expo, through the 27th in Phoenix, as follows:
• Tuesday, 25 March at 11:00 a.m. in Room 106C West: “Big Blue Transgenic Rodent Mutation Assay and Novel Renal Proximal Tubule Epithelial Cell Line (RPTECs) – Fulfillment of an Unmet Need in Genetic Toxicology and Nephrotoxicity.”
• Wednesday, 26 March, at 1:00 pm in Exhibit Hall: “Somatic and Germ Cell Mutant Analysis in the Big Blue Transgenic Mouse Mutation Assay with N-Ethyl-N-nitrosourea (ENU)”. Poster number 362
• Wednesday, 26 March, at 1:00 pm in Exhibit Hall: “Integration of Pig-a and Micronucleus Endpoints into the Big Blue Transgenic Mouse Mutation Assay: Results for Benzo(a)pyrene (BaP) and N-Ethyl-N-nitrosourea (ENU)”. Poster number 363
For more information on the Big Blue Mouse and Rat TRM assay service, click here.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance